PubRank

Immunogenicity of Therapeutic Protein Aggregates.

PubWeight™: 0.82‹?›

🔗 View Article (PMID 26869409)

Published in J Pharm Sci on February 01, 2016

Authors

Ehab M Moussa1, Jainik P Panchal1, Balakrishnan S Moorthy1, Janice S Blum2, Marisa K Joubert3, Linda O Narhi3, Elizabeth M Topp4

Author Affiliations

1: Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907.
2: Department of Microbiology and Immunology, School of Medicine, Indiana University, Indianapolis, Indiana 46202.
3: Amgen Inc., Process Development, Thousand Oaks, California 91320.
4: Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907. Electronic address: topp@purdue.edu.

Articles citing this ↘

Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol (2016) 0.82

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. PLoS One (2016) 0.78

Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab. Biomed Res Int (2017) 0.75

Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies. MAbs (2017) 0.75

Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus (2017) 0.75

AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG. Sci Rep (2017) 0.75

Articles by these authors ⇆

Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. J Pharm Sci (2016) 0.76